CCM
UTHR icon

Cadence Capital Management’s United Therapeutics UTHR Stock Holding History

Cadence Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,976
Closed -$809K – 701
2017
Q1 		$809K Sell
5,976
-4,850
-45% -$735K 0.06% 400
2016
Q4 		$1.55M Buy
+10,826
New +$1.38M 0.11% 235

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cadence Capital Management's UTHR Position: Q2 2017 in Review

Cadence Capital Management sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 5,976 shares — an estimated $809K sold.

Cadence Capital Management first reported a position in UTHR in Q4 2016 and held it in 2 quarters. The position peaked at $1.55M in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

  • Cadence Capital Management reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Cadence Capital Management sold 5,976 United Therapeutics shares in Q2 2017, an estimated $809K.
  • Cadence Capital Management first reported a position in United Therapeutics in Q4 2016 and held it in 2 quarters.
  • Cadence Capital Management's United Therapeutics position peaked at $1.55M in Q4 2016.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Cadence Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.